#cannabisaficionado

Industry Innovators

Medical Cannabis Companies Challenge DEA’s November 29 Supply-Chain Deadline

A federal appeals case challenges the transition rules separating timely applicants and registered businesses from other state-licensed operators.

Published

on

A person signing a paper document at a wooden table.
Advertisement Back2Grow Advertisement

Three medical cannabis companies are asking a federal appeals court to stop a DEA supply-chain deadline that they say could cut off customers, suppliers and jobs. Their emergency motion challenges the agency’s November 29 transition requirement, turning the practical implementation of federal medical-marijuana rescheduling into an immediate business dispute.

The case is Standard Wellness Utah, LLC v. Drug Enforcement Administration, No. 26-1324, in the U.S. Court of Appeals for the District of Columbia Circuit. The source filing contains an emergency motion filed November 18 and a petition bearing a November 19 filing stamp. Those dates should not be collapsed into a single filing date. The companies request relief by November 25; that request is not a court order granting it.

Tom Angell’s November 19 reporting for Marijuana Moment brought the challenge to wider attention. The petitioners are Standard Wellness Utah, Verde Americano in Arizona and NW Confections OK 241AA in Oklahoma. Their predicted financial damage remains their allegation, supported by declarations submitted with the motion, rather than a judicial finding.

What the November 29 deadline covers

The challenged document is the DEA’s October 30 information notice for businesses that submitted complete medical-marijuana registration applications during the April 28–June 26 window. A copy appears in the court package. It says qualifying applicants may continue specified operations under their state licenses while federal applications are pending.

The notice also limits their trading partners to other timely applicants or federally registered medical-marijuana businesses. It says dealing outside those categories could provide grounds to deny an application or revoke a registration. Businesses are expected to verify partners’ status and establish compliant supply chains by November 29.

That is a question about which businesses can transact within a federally recognized medical supply chain. It is not a new patient prescription, permission for adult-use sales or a declaration that every state cannabis company has federal registration. The distinction matters because a customer’s state license and its status in the federal application process answer different questions.

What the companies say could happen

Standard Wellness Utah says it faces the loss of customers generating approximately $275,900 in average monthly sales and suppliers providing about 16 percent of its oil. The motion says some trading partners have already refused transactions, including a pharmacy holding roughly $80,000 of previously delivered product apart from other inventory.

Verde says important Arizona customers have demanded evidence of its federal status and one large customer paused orders. Its declaration predicts a 70 percent workforce reduction if the challenged restrictions remain. NW Confections identifies 15 affected dispensary customers operating about 23 Oklahoma locations and says the loss of those relationships threatens its business.

These are specific forecasts from companies seeking emergency relief. They show the scale of harm alleged, but do not establish that every projected loss will occur. The filings also describe state restrictions on interstate commerce as a reason replacement suppliers or customers cannot simply be found in another state.

The agency notice contains qualifications

The notice allows timely dispensers and distributors to continue otherwise authorized use of existing inventory acquired before the October 30 information document, including inventory previously obtained from businesses outside the timely-applicant or registered categories. That qualification complicates any claim that every affected product must disappear on November 29.

It also describes limited discretion for sending small quantities to certain same-state testing laboratories where a DEA-registered option is unavailable under the stated conditions. That language is narrow. It should not be read as a general exemption covering all laboratory transactions or all businesses without registration.

The document ends by saying it provides clarity about existing requirements and does not itself have the force of law. The companies argue that its practical restrictions nevertheless operate like a binding rule. That disagreement is central to the case, rather than something the filing resolves on its own.

What the court is being asked to decide

The motion advances three principal arguments: that the notice conflicts with the April rescheduling framework, that DEA imposed a legislative rule without notice and comment, and that the agency failed to adequately consider reliance interests and disruption. These are the petitioners’ legal positions, not this article’s conclusions about the agency’s authority.

A stay would address whether the challenged requirements should pause while litigation proceeds. It would not automatically decide every issue surrounding federal cannabis regulation. Our earlier supply-chain explainer covers the underlying transition; this case adds a direct court challenge. The next meaningful development is a docketed response or court order, rather than the mere passage of the companies’ requested decision date.

Illustrative paperwork stock photograph; not a petitioner, DEA official, court filing or scene from this lawsuit. Photo: Matheus Lara / Pexels.

Industry Innovators

MÜV Plans a November 20 Tarpon Springs Opening for Florida Medical Patients

The announced Friday opening adds another MÜV address before Thanksgiving, while Florida’s medical-program eligibility and documentation remain unchanged.

Published

on

A black sign reading Come In, We Are Open hanging on glass.

Verano says its new MÜV dispensary in Tarpon Springs will open Friday, November 20, adding a medical-cannabis location ahead of Thanksgiving week. The November 19 announcement places the store at 40084 US Highway 19 North. For patients, the new address expands the company’s retail network; it does not change Florida’s requirements for purchasing medical marijuana.

The opening and the ceremonial celebration fall on different days. Verano lists Friday as the first day of business and Monday, November 23, at 9 a.m. for the ribbon cutting. Anyone planning a visit should distinguish the operating start from the later event and check current store information before traveling.

What the company has announced

According to Verano’s release, Tarpon Springs will bring its Florida network to 89 MÜV locations and its national dispensary count to 166. The company lists Monday–Saturday hours of 9 a.m.–8 p.m. and Sunday hours of 10 a.m.–5 p.m., all local time. Those are announced hours, rather than an independent report from inside the new store.

The company also describes virtual and in-store patient consultations, online menus and express pickup ordering. Those services can help patients understand the shop’s offerings, but a retail consultation is different from the qualified physician’s role in determining eligibility and treatment. The opening announcement does not establish that every listed product will be available at every moment.

For an existing patient, the practical question is whether the location offers a more convenient way to fill an authorized order. Store count alone does not show shorter travel times for every household, lower prices across the market or an improvement in medical outcomes. Those would require separate evidence.

Who may purchase medical cannabis in Florida?

Florida’s Office of Medical Marijuana Use patient guidance sets out the path to treatment. A patient must be a permanent or seasonal Florida resident, receive a qualifying diagnosis from a qualified physician, be entered into the Medical Marijuana Use Registry and obtain a registry identification card. Opening another shop does not bypass that process.

The state says patients and caregivers may purchase only from an approved medical marijuana treatment center. Once the card application is approved, they can contact an MMTC to fill the physician’s order. A nearby store may make that transaction easier, but it is not the place to assume that an ordinary retail purchase can replace an active medical authorization.

The guidance also recognizes delivery by licensed treatment centers. Patients without an MMTC in their own city can contact a licensed provider about delivery. Whether pickup or delivery is more practical depends on the provider’s current service area and the patient’s circumstances, rather than the existence of a new storefront alone.

Check the card and the order separately

The state’s identification-card information says an active card is required to purchase and possess medical marijuana. Cards expire one year after approval, and renewals are handled through the state process. The page directs patients to submit renewal applications within the designated period before expiration, rather than treating a dispensary visit as renewal.

That administrative requirement is separate from a physician’s certification and orders. Patients preparing for holiday travel or a new store visit should check both parts of their records. A valid-looking card and a current order answer different questions, so a problem with either is best resolved before arriving at the counter.

Florida’s program FAQ says that, beginning July 27, 2026, an initial or renewal card application cannot be completed without current or scheduled certifications with open orders in the registry. It directs questions about certifications and orders to the patient’s qualified physician. A promotional opening date does not change that clinical responsibility.

Planning a visit during Thanksgiving week

A sensible first check is the store’s current menu, followed by its hours and pickup arrangements. Ask how an order is confirmed, what identification is required and whom to contact if a registry issue appears. These are ordinary planning questions, not a recommendation to buy a particular product or increase an existing order.

Holiday promotions also deserve to be considered separately from medical decisions. A discount can affect a transaction’s price, but it cannot establish that a formulation, strength or route is appropriate for an individual patient. The physician remains the relevant person for treatment questions, while store staff can explain availability and the retail process.

Tarpon Springs’ announced opening gives qualified patients another MÜV location to consider. The useful distinction is between access and authorization: one more storefront may offer a more convenient option, while eligibility, active documentation and the physician’s order remain part of Florida’s medical program. The Friday opening and Monday ceremony are the next concrete milestones to verify.

Illustrative retail-opening stock photograph; not MÜV Tarpon Springs, its signage or its premises. Photo: Nicu Cobasnean / Pexels.

Continue Reading

Industry Innovators

Novi’s Cannabis Business Conference Puts Retail, Policy and Branding on the Agenda

The announced program pairs cannabis operating questions with a planned appearance by FUBU founder Daymond John, without implying a product endorsement.

Published

on

A white lectern in front of rows of empty conference chairs.

Power Connections Cannabis is scheduled for November 20 in Novi, Michigan, bringing cannabis retailers, processors and business-service providers together for a day focused on how the industry operates. The program pairs policy and commercial discussions with a planned appearance by FUBU founder Daymond John, connecting cannabis business questions with experience built in fashion and branding.

The organizer’s published agenda lists the Vibe Credit Union Showplace as the venue and a late-afternoon fireside chat with John. It also includes sessions on advocacy, business operations and collaboration between brands and retailers. This is a preview of the announced program, not a report that every session occurred as planned or that speakers made particular comments there.

A branding conversation, not a product endorsement

John’s own speaking biography identifies his background as FUBU’s founder and chief executive and emphasizes marketing, negotiation and business development. His appearance at a cannabis conference is relevant to a sector trying to build recognizable brands within a regulated market. It does not establish that he uses cannabis, endorses a particular product or has announced a cannabis clothing collaboration.

The distinction is useful for readers who know him primarily through fashion and television. Experience building a consumer brand can inform a business conversation without turning the event into a fashion launch. A speaker listing also should not be treated as evidence that a participant has invested in any company represented in the room.

For cannabis operators, the practical question is what can be learned about reaching customers while preserving the requirements that make this market different. Branding, distribution, pricing and compliance have to work together; a memorable logo alone does not answer those operational questions.

The state’s October figures provide context

Michigan’s Cannabis Regulatory Agency October statistical report records approximately $252.87 million in adult-use product sales for October 1–31. Flower accounted for about $102.71 million, while vape cartridges accounted for approximately $49.06 million. Those figures describe statewide reported sales, not the revenue of conference participants.

The same report lists an average retail flower price of $59.61 per ounce. That is an aggregate measure, not a promise that a particular store offers an ounce at that price or that every product has comparable quality. The data also separate categories such as flower, concentrates and infused products rather than treating all cannabis as one interchangeable item.

That variety helps explain why a business conference can cover several different commercial problems. A brand selling packaged edibles, a cultivator supplying flower and a retailer building a menu occupy different positions in the chain. Statewide sales totals establish the market’s scale, but do not show that every operator is profitable.

A tax benchmark is not a shelf price

Michigan Treasury’s fourth-quarter wholesale price guidance lists flower at $630.81 per pound for October through December. It explains that its calculation uses sales information and an assumed wholesale-to-retail markup, rather than simply publishing a live quote from a wholesaler.

The agency combines spending and quantities across the period used, then converts the resulting retail average using an assumption that retail prices are 50 percent higher than wholesale prices. In that method, the retail figure is divided by 1.5. Comparing this benchmark directly with a dispensary promotion would mix measures serving different purposes.

Treasury also treats product categories and measurement units separately. Some values are expressed per pound and others per fluid ounce. For businesses, that makes classification and recordkeeping part of the commercial discussion, alongside sales strategy. For readers, it is a reason to ask what a quoted price actually measures before treating it as a market-wide deal.

A cannabis conference is not automatic consumption permission

Michigan’s judicial benchbook on the adult-use law distinguishes lawful adult possession from public consumption and property rules. The law does not generally authorize consuming in public, and property owners or managers can regulate cannabis activity on their premises. Designated consumption areas require the relevant authorization.

Nothing in the published conference agenda should be read as independent proof that this venue has authorized cannabis consumption. Likewise, state legalization does not authorize driving under the influence. Those boundaries remain relevant when an event uses cannabis in its title, because a business gathering and a licensed consumption event are different things.

The value of today’s announced program is its focus on the connections between policy, retail and business execution. Any conclusions about attendance, deals completed or lessons delivered will require reporting after the event. Until then, the agenda establishes what organizers planned, while the state’s records provide the operating context around it.

Illustrative conference stock photograph; not Power Connections, the Vibe Credit Union Showplace or its speakers. Photo: Nacho Gomez / Pexels.

Continue Reading

Industry Innovators

Decibel’s Export Growth Offsets a Weaker Canadian Cannabis Quarter

International sales reached C$12.1 million as Decibel reported higher overall revenue and acknowledged work still needed in its Canadian business.

Published

on

A flowering cannabis plant among rows of plants supported by netting.

Decibel Cannabis reported higher quarterly revenue November 19, with international sales offsetting a weaker Canadian recreational business. Net revenue reached C$35.1 million for the three months ended September 30, up 7% from a year earlier. The contrast between its two markets is the central story: international sales rose 44% to C$12.1 million, while domestic sales fell 6% to C$23.0 million.

The Canadian cannabis company also issued its first quarterly shareholder letter, pairing results with management’s account of where the business needs work. Together, the documents describe an exporter gaining momentum while trying to rebuild performance at home. They are company disclosures, not independent confirmation that its strategy will deliver future growth.

What Decibel’s third-quarter results show

In its corrected November 19 release, Decibel reported C$7.4 million in adjusted EBITDA and C$1.1 million in free cash flow. Gross margin before fair-value adjustments was 52%, compared with 47% a year earlier. All dollar figures here are Canadian dollars.

Management reaffirmed full-year net-revenue guidance of C$132 million to C$137 million and adjusted EBITDA of C$28 million to C$32 million. Those ranges are forecasts, not completed annual results. The company identifies adjusted EBITDA and free cash flow as non-GAAP measures, which means they should be read alongside its financial statements rather than treated as substitutes for conventional earnings or operating cash flow.

The figures answer different questions. Revenue measures sales; a margin describes the relationship between revenue and specified costs; cash flow concerns money moving through the business. Growth in one does not establish equivalent progress in all three. That is particularly useful context when international expansion is carrying more of the sales total.

Management’s letter puts Canada in focus

The shareholder letter, signed by executive chairman Shawn Dym and chief executive Benjamin Sze, acknowledges that Canadian execution needs improvement. Management says it changed commercial leadership during the quarter and intends to address gaps in flower and standard pre-rolls under General Admission.

The letter describes international business as roughly 35% of quarterly revenue, compared with about 4% in 2024. It says AgMedica operated at approximately 42% of its annual processing capacity during the quarter. Those are management’s descriptions of the business, not a guarantee that unused capacity will turn into sales.

The distinction matters because capacity is only one part of an export operation. A facility can have room to process more material while still needing customers, approvals, shipments and repeat orders. Our reading is that the next test is whether the larger international business becomes durable, rather than whether another theoretical production ceiling can be announced.

Management says future letters will revisit sell-through and reorders, Canadian market share, international revenue and AgMedica utilization. That creates a useful set of measures to compare over time. A later quarter can show whether customer demand repeats and whether domestic changes are producing results; the first letter alone cannot establish either outcome.

Why cannabis exports require more than a buyer

Health Canada’s export guidance provides the regulatory backdrop. Under the Cannabis Regulations, licensed businesses may export cannabis only for medical or scientific purposes. A separate Health Canada permit is required for each shipment. This is not a general export channel for Canadian adult-use products.

The agency considers the destination country’s import permit, treaty obligations, the intended medical or scientific use, and public-health and security questions. That means a commercial supply agreement and permission to ship are distinct steps. An announcement about an overseas customer should not automatically be counted as a completed export or recognized revenue.

For readers following the industry, this helps explain why international opportunity can coexist with uneven quarterly results. The relevant questions extend beyond brand recognition: can the supplier satisfy the importing market’s requirements, deliver consistently and keep the relationship after the first order? National legalization at home does not remove those cross-border conditions.

What to watch in the next report

The clearest follow-up will be the relationship between international growth and Canadian performance. An exporter can report a stronger combined number while one segment contracts. Looking at both prevents a headline about total sales from obscuring the work still needed in the larger domestic business.

It will also be useful to compare cash generation with the pace of expansion. More sales can require more resources before customers pay. A growing revenue line therefore deserves to be considered together with the cash-flow statement and management’s explanation of working capital, rather than in isolation.

Decibel’s quarter shows how differently the same cannabis company can perform across markets. The reported export gains are substantial, and the domestic decline remains part of the result. The next disclosures will help establish whether international momentum persists while the Canadian business improves.

Illustrative cannabis-cultivation stock photograph; not Decibel, AgMedica, their products or their facilities. Photo: Cannafornia / Pexels.

Continue Reading

Trending

Join The Cannabis Aficionado Community!
Join the Cannabis Aficionado community and receive all of the most relevant news geared towards our sophisticated enthusiast community.
Loading

Copyright ©️ 2026 Cannabis Aficionado. Cannabis Aficionado is a registered trademark of CNM Inc. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service, Privacy Policy and Cookies Policy. People may receive compensation for some links to products and services. Offers may be subject to change without notice.